Why the study?
Does biomarker-guided monitoring (cardiac troponin) and targeted preventive therapy improve clinical outcomes and prevent cardiotoxicity in patients undergoing cancer therapy?
Does biomarker-guided monitoring (cardiac troponin) and targeted preventive therapy improve clinical outcomes and prevent cardiotoxicity in patients undergoing cancer therapy?
Biomarker-guided monitoring using cardiac troponin allows for early identification of cancer patients at high risk for cardiotoxicity, enabling targeted cardioprotective therapy with ACE inhibitors.
Answers are grounded in this paper and cite their sources.
May enable earlier cardiotoxicity detection before functional decline; leaves open prospective validation before clinical adoption.
INTRODUCTION: Cardiotoxicity is a common complication that may compromise the clinical effectiveness of anticancer therapy. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategy. Areas covered: A novel approach, based on the use of biomarkers has recently emerged, resulting in a very effective tool for early, real-time identification, and monitoring of cardiotoxicity. In particular, cardiac troponin elevation during chemotherapy allows to identify patients more prone to develop myocardial dysfunction and cardiac events. In these patients, use of angiotensin-converting enzyme inhibitors, such as enalapril, has shown to be effective in improving clinical outcomes, giving the chance for cardioprotective strategies in a selected population. The authors reviewed the currently available data about the role of biomarkers in this setting. Expert commentary: Early identification of patients at high risk of cardiotoxicity by cardiac biomarkers - in particular troponin - provides a rationale for targeted preventive strategies against cancer therapy-induced left ventricular dysfunction and its associated clinical complications, with the advantage of limiting prophylactic therapy only to a restricted number of patients. Although the major international oncologic societies encourage this approach, some limitations to a routinely use of biomarkers still exist.
No takes yet. Share an insight, caveat, or question.
Cardinale et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: